Survival Differences Between De Novo and Recurrent HER2-Positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Oncology · 14.11.2026
DOI: 10.1159/ocl/aebag029 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Oncology, online erschienen am 14.11.2026. Verfasst von Taiga Komatsu und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Although several studies have reported better survival outcomes in patients with de novo HER2-positive metastatic breast cancer (MBC) compared with those with recurrent disease, findings have been inconsistent across studies. This systematic review and meta-analysis aimed to assess differences in progression-free survival (PFS) and overall survival (OS) between patients with de novo and recurrent HER2-positive MBC.
Methods
A systematic search of PubMed and Web of Science was conducted from inception to June 20, 2026, following PRISMA 2020 guidelines. Eligible studies included prospective or retrospective cohort, registry-based, or population-based studies comparing survival outcomes between de novo and recurrent HER2-positive MBC. Meta-analyses were performed using random-effects models. Publication bias was assessed using funnel plots, and sensitivity analyses were conducted using fixed-effects models.
Results
14 studies comprising 6,213 patients were included. The pooled hazard ratio (HR) was 0.74 (95% CI 0.65-0.83, p<0.0001) for PFS and 0.67 (95% CI 0.60-0.75, p<0.0001) for OS, favoring de novo presentation. Further analyses restricted to studies reporting adjusted HRs confirmed consistent results for both PFS (HR 0.70, 95% CI 0.61-0.80) and OS (HR 0.71, 95% CI 0.61-0.82). Funnel plots showed no significant evidence of publication bias. Sensitivity analyses using fixed-effects models yielded concordant findings for both PFS (HR 0.72, 95% CI 0.66-0.78) and OS (HR 0.66, 95% CI 0.61-0.72).
Conclusions
Patients with de novo HER2-positive MBC have significantly better PFS and OS compared with recurrent disease. Metastatic presentation status should be considered as a stratification factor in future clinical trials.
Autor:innen und Institutionen
ORCID-Profile: Amy Tiersten
Zitieren
APA
Komatsu, T., Osawa, H., Cronin, K., Okazawa, K., Suzuki, T., & Tiersten, A. (2026). Survival Differences Between De Novo and Recurrent HER2-Positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. Oncology. https://doi.org/10.1159/ocl/aebag029
Vancouver
Komatsu T, Osawa H, Cronin K, Okazawa K, Suzuki T, Tiersten A. Survival Differences Between De Novo and Recurrent HER2-Positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. Oncology. 2026. doi:10.1159/ocl/aebag029
BibTeX
@article{Komatsu2026,
author = {Komatsu, Taiga and Osawa, Hanna and Cronin, Keri and Okazawa, Ken and Suzuki, Takao and Tiersten, Amy},
title = {Survival Differences Between De Novo and Recurrent HER2-Positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis},
journal = {Oncology},
year = {2026},
doi = {10.1159/ocl/aebag029}
}
EUVIMED